Sumary of Shark vNAR antibodies inhibit SARS-CoV-2 variants in vitro:
- Researchers in the UK and Austria have identified a novel class of antibodies that is highly effective at neutralizing the original strain of severe acute respiratory syndrome (SARS-CoV-2) and maintaining blocking activity against certain viral variants that have emerged..
- The team identified ten single domain shark variable new antigen receptor (VNAR) antibody fragments that were highly effective at blocking the binding of the SARS-CoV-2 surface spike protein to its human host cell receptor angiotensin-converting enzyme 2 (ACE2)..
- The VNAR antibodies blocked the interaction between the receptor-binding domain (RBD) of the original Wuhan-Hu-1 spike protein and the ACE2 receptor..
- The antibodies also blocked this interaction when the spike proteins tested contained mutations found in the B.1.351 variant that emerged in South Africa and the P.1 variant that emerged in Brazil..
- “VNAR antibodies directed against the SARS-CoV-2 spike protein expand the molecular toolbox of novel therapeutic approaches against COVID-19,”.
- The progress so far in combatting COVID-19 The initial step of the SARS-CoV-2 infection process is mediated by the viral spike protein when its RBD attaches to the host cell receptor ACE2..
- The S1 subunit contains the RBD (S1-RBD), which makes direct contact with ACE2, while the S2 subunit drives host cell entry by enabling viral fusion to the cell membrane..
- This domain, therefore quickly became the main focus of efforts to develop vaccines and antibody therapeutics for the prevention and treatment of COVID-19….